Novartis AG

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020) Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Conference contribution Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study (2020) McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, et al. Journal article Measurement of Skeletal Muscle Fiber Contractility with High-Speed Traction Microscopy (2020) Böhringer D, Rausch M, Steinmann M, Schrüfer S, Schubert DW, Haertl A, Mark C, Fabry B Conference contribution Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (2020) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Psoriasis Patients are still severely underserved: Results of the DERMLINE Online Survey (2020) Hell K, Schielein MC, Romer K, Hacker E, Baeumer D, Wagner N, Zink A Conference contribution Patients with Chronic Urticaria need better Treatment: Results of the DERMLINE Online Survey (2020) Hell K, Zink A, Schielein MC, Hacker E, Romer K, Baeumer D, Wagner N Conference contribution Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. (2020) De Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, D'Amato L, et al. Journal article Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study (2020) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Journal article Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study (2020) Reich K, Koerber A, Mrowietz U, Sticherling M, Sieder C, Frueh J, Bachhuber T Journal article